trial

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

NCTId NCT06923891
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Not Yet Recruiting
Enrollment 172 (estimated)
Sponsored by Vanguard Research Group
Primary completion 2026-10-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Not Yet Recruiting
Enrollment
172 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-04-16
Primary completion
2026-10-30
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Vanguard Research GroupLead Sponsor
Bristol-MyersCollaborator

Sites

1 total
Richmond, United States

Facts & assertions

4 sourced
Enrollment
172
Phase
PHASE4
Primary Completion Date
2026-10-30
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Vanguard Research Group
company
collaborator
Bristol-Myers
company
indication
Schizophrenia
indication
Schizophrenia
indication